DoW Prostate Cancer, Early Investigator Research Award

The Defense Health Agency, through the Congressionally Directed Medical Research Programs, administers the Prostate Cancer Research Program Early Investigator Research Award. This program is part of a broader federal effort initiated by Congress in 1997 to support innovative and impactful prostate cancer research, with cumulative appropriations exceeding billions of dollars. The program is designed to cultivate the next generation of prostate cancer researchers by providing early-career investigators with funding, mentorship, and structured research development opportunities. It operates under statutory authority and is managed within the Department of Defense research infrastructure, reflecting a strong emphasis on improving outcomes for Service Members, Veterans, and the general public. The primary purpose of this award is to support early-career investigators in conducting prostate cancer-focused research while developing their professional research capabilities. Applicants must propose projects that align with one of the program’s overarching challenges, which include improving survivorship and quality of life, developing or enhancing treatments for lethal prostate cancer, improving clinical care, or advancing understanding of disease progression. The program emphasizes high-impact, translational research that can lead to meaningful improvements in patient outcomes and quality of life. Investigators are expected to demonstrate both scientific rigor and a clear trajectory toward becoming independent researchers. Funding for this opportunity is substantial, with total program funding expected to support approximately fourteen awards. Each award provides up to 630,000 dollars in total costs over a maximum performance period of three years. Funds may be used for a variety of research-related expenses, including travel for collaboration and dissemination, clinical research costs, and workshop participation. However, certain restrictions apply, such as prohibitions on funding for equipment purchases, clinical trials, and salary support for mentors or senior personnel other than the principal investigator. Cost sharing is not required, making the program accessible to a broad range of institutions. Eligibility is inclusive of both domestic and international organizations, including academic institutions, government entities, and private sector organizations. Principal investigators must meet strict early-career criteria, including possession of a doctoral degree and no more than three years of postdoctoral research experience at the time of application submission, excluding clinical training periods. Each application must include at least one qualified mentor with demonstrated expertise in prostate cancer research and mentorship. The program also requires a detailed researcher development plan outlining how the investigator will acquire necessary skills and advance toward independence. The application process consists of two required steps: submission of a pre-application, typically a letter of intent, followed by a full application. The pre-application is submitted through the Electronic Biomedical Research Application Portal, while full applications may be submitted through either that system or Grants.gov depending on the applicant organization type. The full application requires multiple components, including a project narrative, technical and lay abstracts, a statement of work, a researcher development plan, and various supporting documents such as letters of support and data sharing plans. Applications are evaluated through a two-tier review process consisting of peer review and programmatic review, with criteria focused on investigator potential, mentorship quality, research strategy, development planning, and overall impact. The timeline for this funding opportunity includes a pre-application deadline in August and a full application deadline in early September, with subsequent peer review occurring in late fall and programmatic review in early spring. Awards are expected to be finalized by the following fiscal year, with funds available for use through a defined expiration period. Applicants are encouraged to begin preparations early due to registration requirements and the complexity of submission components. The program does not screen pre-applications for advancement, allowing all eligible applicants to proceed to full submission after completing the initial step. Overall, this funding opportunity represents a structured and competitive mechanism for fostering early-career talent in prostate cancer research. It combines financial support with mentorship and professional development expectations, aiming to accelerate both scientific discovery and investigator growth. The emphasis on rigorous research design, alignment with strategic challenges, and measurable impact underscores the program’s commitment to advancing the field and improving patient outcomes.

Ensure strong mentor track record and clear mentorship plan; align proposal with one overarching challenge; emphasize investigator career development and independence; demonstrate rigorous and feasible research design